Drugs / Thioctic Acid

Trials 6 · a red edge is where a trial was stopped

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01808300 Feb → Jul 2013 Unimed Pharmaceuticals Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00002154 HIV infectious disease, cognitive disorder The Dana Foundation Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00328601 Feb → Jun 2005 diabetic polyneuropathy MEDA Pharma GmbH & Co. KG Completed No outcome recorded
Phase 3 NCT00977483 May 1998 → Jan 2005 diabetic polyneuropathy MEDA Pharma GmbH & Co. KG Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03914404 Jan → Mar 2016 diabetic polyneuropathy Chonbuk National University Hospital Completed No outcome recorded
Phase not applicable1 trial
NCT00004770 Oct 1995 → ? pure mitochondrial myopathy National Center for Research Resources (NCRR) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06253429 Comparator Jan 2023 → Jan 2024 type 1 diabetes mellitus Ain Shams University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Thioctic acid ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002154
6

NCT01808300

NCT00977483

NCT00328601

NCT03914404

NCT06253429

NCT00004770

Known as alpha-lipoic acid “600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial” NCT00977483
Known as LipoA HR Tab. 600mg “Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.” NCT03914404
Route Oral orally (tablet) administered thioctic acid” NCT00328601